Leiden-based biotechnology company developing Synerkines, novel cytokine fusion proteins that combine immunoregulatory activity to modulate targets in pain pathways
Leiden-based biotechnology company developing Synerkines, novel cytokine fusion proteins that combine immunoregulatory activity to modulate targets in pain pathways. Its therapeutics are designed as non-opioid treatments for chronic pain, including complex regional pain syndrome, with a mechanism differentiated from existing analgesics.